WallStreetZenWallStreetZen

NASDAQ: PHAR
Pharming Group Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PHAR stock forecasts and price targets.

Forecast return on equity

Is PHAR forecast to generate an efficient return?

Company
25.93%
Industry
350.65%
Market
211.89%
PHAR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHAR forecast to generate an efficient return on assets?

Company
14.49%
Industry
116.31%
PHAR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHAR earnings per share forecast

What is PHAR's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.04
Avg 2 year Forecast
$0.04
Avg 3 year Forecast
$0.06

PHAR revenue forecast

What is PHAR's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$388.7M-8.8%
Avg 2 year Forecast
$401.7M-5.75%
Avg 3 year Forecast
$403.9M-5.24%
PHAR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PHAR revenue growth forecast

How is PHAR forecast to perform vs Biotechnology companies and vs the US market?

Company
-1.19%
Industry
117.27%
Market
22.74%
PHAR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PHAR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PHAR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHAR$17.67N/AN/A
BHVN$11.29$27.08+139.83%Strong Buy
TNGX$8.86$12.40+39.95%Strong Buy
OMER$17.18$33.67+96.02%Strong Buy
PHAT$16.59$21.00+26.58%Buy
View Top Biotech Stocks

Pharming Group Nv Stock Forecast FAQ

What is PHAR's earnings growth forecast for 2026-2028?

(NASDAQ: PHAR) Pharming Group Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 67.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.64%.

Pharming Group Nv's earnings in 2025 is $444,186.On average, 9 Wall Street analysts forecast PHAR's earnings for 2026 to be $26,736,133, with the lowest PHAR earnings forecast at -$33,335,128, and the highest PHAR earnings forecast at $115,720,516. On average, 8 Wall Street analysts forecast PHAR's earnings for 2027 to be $25,103,392, with the lowest PHAR earnings forecast at -$33,335,128, and the highest PHAR earnings forecast at $75,718,362.

In 2028, PHAR is forecast to generate $41,770,956 in earnings, with the lowest earnings forecast at $6,939,149 and the highest earnings forecast at $77,623,227.

If you're new to stock investing, here's how to buy Pharming Group Nv stock.

What is PHAR's revenue growth forecast for 2026-2028?

(NASDAQ: PHAR) Pharming Group Nv's forecast annual revenue growth rate of -1.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.

Pharming Group Nv's revenue in 2025 is $421,248,837.On average, 9 Wall Street analysts forecast PHAR's revenue for 2026 to be $264,429,202,207, with the lowest PHAR revenue forecast at $227,012,221,782, and the highest PHAR revenue forecast at $306,873,664,184. On average, 9 Wall Street analysts forecast PHAR's revenue for 2027 to be $273,266,412,675, with the lowest PHAR revenue forecast at $174,941,391,205, and the highest PHAR revenue forecast at $350,665,137,456.

In 2028, PHAR is forecast to generate $274,769,894,979 in revenue, with the lowest revenue forecast at $250,591,722,537 and the highest revenue forecast at $299,846,074,951.

What is PHAR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PHAR) forecast ROA is 14.49%, which is lower than the forecast US Biotechnology industry average of 116.31%.

What is PHAR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PHAR) Pharming Group Nv's current Earnings Per Share (EPS) is $0.00. On average, analysts forecast that PHAR's EPS will be $0.04 for 2026, with the lowest EPS forecast at -$0.05, and the highest EPS forecast at $0.17. On average, analysts forecast that PHAR's EPS will be $0.04 for 2027, with the lowest EPS forecast at -$0.05, and the highest EPS forecast at $0.11. In 2028, PHAR's EPS is forecast to hit $0.06 (min: $0.01, max: $0.11).

What is PHAR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PHAR) forecast ROE is 25.93%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.